C4 Therapeutics says cemsidomide-elranatamab Phase 1b trial clears 75 µg dose as safe in multiple myeloma

• C4 Therapeutics presented new biomarker results at the 23rd International Myeloma Society annual meeting.
• Phase 1 data in relapsed or refractory multiple myeloma supported immune activation with cemsidomide plus dexamethasone, consistent with prior anti-myeloma activity.
• Early Phase 1b biomarker readouts in the first two patients suggested cemsidomide may strengthen T-cell function with Pfizer’s elranatamab.
• A safety committee cleared the initial 75 µg dose level in the elranatamab combination, enabling escalation and expansion cohorts.
• Results from all Phase 1b cohorts are expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250700PRIMZONEFULLFEED9833757) on September 25, 2026, and is solely responsible for the information contained therein.